Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Jeremiah Mead, Architect Of Respiratory Mechanics Field, Dies
Jeremiah (Jere) Mead, architect of the field of respiratory mechanics and Professor Emeritus in the Department of Environmental Health at the Harvard School of Public Health (HSPH), passed away on July 4, 2009, at a health care facility in Ellsworth, ME. He was 88 years old.
generic viagra online
Ohio State Start-Up To Commercialize MRI-Compatible Treadmill
An Ohio State University researcher is shifting his development of an MRI-compatible treadmill to his start-up company and plans to have a device ready for clinical testing in three months. The treadmill could allow physicians to measure a patient"s heart during peak stress more accurately than the echocardiograph and nuclear imaging processes now widely used.
News of the day
Breast MRI Detects Additional "Unsuspected" Cancers Not Seen On Mammography Or Ultrasound
Nearly 20% of patients with recently diagnosed breast cancer had additional malignant tumors found only by MRI, according to a study performed at Dartmouth Hitchcock Medical Center.
Endocrinology

FDA Approves Effient To Reduce The Risk Of Heart Attack In Angioplasty Patients

The U.S. Food and Drug Administration has approved the blood-thinning drug Effient tablets (prasugrel) to reduce the risk of blood clots from forming in patients who undergo angioplasty, a common procedure to unblock a clogged coronary artery. During an angioplasty, a balloon is used to open the artery that has been narrowed by atherosclerotic plaque.Often, a tiny wire mesh scaffold (stent) is inserted into the blood vessel to help keep the artery open after the procedure. Platelets in the blood can clump around the procedure site, causing clots that can lead to heart attack, stroke, and death. Effient was studied in a 13,608-patient trial comparing it to the blood-thinning drug, Plavix (clopidogrel), in patients with a threatened heart attack or an actual heart attack who were about to undergo angioplasty. The fraction of patients who had subsequent non-fatal heart attacks was reduced from 9.1 percent in patients who received Plavix to 7.0 percent in patients who received Effient.While the numbers of deaths and strokes were similar with both drugs, patients with a history of stroke were more likely to have another stroke while taking Effient. In addition, there was a greater risk of significant, sometimes fatal bleeding seen in patients who took Effient. "Effient offers physicians an alternative treatment for preventing dangerous blood clots from forming and causing a heart attack or stroke during or after an angioplasty procedure," said John Jenkins, M.D., director of the Office of New Drugs, in the FDA"s Center for Drug Evaluation and Research."Physicians must carefully weigh the potential benefits and risks of Effient as they decide which patients should receive the drug." The drug"s labeling will include a boxed warning alerting physicians that the drug can cause significant, sometimes fatal, bleeding. The drug should not be used in patients with active pathological bleeding, a history of mini-strokes (transient ischemic attacks) or stroke, or urgent need for surgery, including coronary artery bypass graft surgery. Effient is manufactured by Eli Lilly and Company of Indianapolis, in partnership with Tokyo-based Daiichi Sankyo Ltd. U.S. Food and Drug Administration


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009